Vecima Announces Q3 Fiscal 2025 Results Earnings Call
VICTORIA, British Columbia — Vecima Networks Inc. (TSX: VCM) today announces that it will hold a conference call and live audio webcast on Thursday, May 15, 2025, at 1:00 p.m. (ET) to discuss its financial and operational results for the three and nine months ended March 31, 2025.
Article content
A news release announcing the results will be issued the day of the call before markets open. Management will begin the call with their commentary on the three and nine months ended March 31, 2025. Following management's presentation, there will be a question-and-answer session for analysts and institutional investors.
Article content
To participate in the Q3 FY2025 teleconference, dial 1-833-752-3965 or 1-647-849-3105.
Article content
About Vecima Networks
Vecima Networks Inc. (TSX: VCM) is leading the global evolution to the multi-gigabit, content-rich networks of the future. Our talented people deliver future-ready software, services, and integrated platforms that power broadband and video streaming networks, monitor and manage transportation, and transform experiences in homes, businesses, and everywhere people connect. We help our customers evolve their networks with cloud-based solutions that deliver ground-breaking speed, superior video quality, and exciting new services to their subscribers. There is power in connectivity – it enables people, businesses, and communities to grow and thrive. Learn more at vecima.com.
Article content
Article content
Article content
Article content
Article content
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
The Market Online
33 minutes ago
- The Market Online
Gold Report: M&A, record results and near-term production
G2 Goldfields (TSX:GTWO) releases record assays from drilling at its New Oko discovery in Gayana's Oko-Aremu district. Company resources in the district stand at 1.5 million ounces of gold indicated and 1.6 million ounces inferred. Click here for the full story. This content has been prepared as part of a partnership with G2 Goldfields, Mandalay Resources, Lahontan Gold, Ascot Resources, New Found Gold and Sirios Resources, and is intended for informational purposes only. By the ounce At the time of writing on Wednesday, the price of gold was US$3,345.90, up from US$3,303.69 per ounce in our July 9 report, according to data from The Globe and Mail, continuing its range-bound behavior since April following an onslaught of new U.S. tariffs on global partners. This week in gold Mandalay Resources (TSX:MND) reports steady sales of 42,208 ounces of gold and 279 tons of antimony through the first half of 2025 as it prepares to nearly double in size following a merger slated to close in August. Kimberly Ann, founder and chief executive officer of Lahontan Gold (TSXV:LG), delves into how the junior miner is leveraging new permits, multiple drills rigs and full-scale metallurgical testing to unlock near-term production potential at its Santa Fe project in Nevada, which holds an estimated 2 million ounces in gold equivalent resources while offering multi-million-ounce potential still to be reaped. Finally, with the price of gold hovering over US$3,000 per ounce since Q1, handily outperforming the global stock market over the period, major miners are flush with cash and keen to grow resources by acquisition. Read about Ascot Resources (TSX:AOT), New Found Gold (TSXV:NFG) and Sirios Resources (TSXV:SOI), three junior gold explorers that deserve to be squarely in their focus. Top trending gold stocks Join the discussion: Find out what everybody's saying about the stocks in this week's gold report on Stockhouse's stock forums and message boards. Stockhouse does not provide investment advice or recommendations. All investment decisions should be made based on your own research and consultation with a registered investment professional. The issuer is solely responsible for the accuracy of the information contained herein. For full disclaimer information, please click here.
Cision Canada
an hour ago
- Cision Canada
Oncolytics Biotech® Presents Aggregated Translational Data Providing Evidence of Pelareorep's Effectiveness Across Multiple Tumor Types
Integrated biomarker analyses confirm viral replication, interferon signaling, and a surge in tumor-infiltrating lymphocytes after pelareorep treatment Cross-study data show pelareorep increases PD-L1 expression and boosts cytotoxic T-cell activity, priming resistant tumors for checkpoint inhibitors SAN DIEGO and CALGARY, AB, July 16, 2025 /CNW/ -- Oncolytics Biotech ® Inc. (NASDAQ: ONCY) (TSX: ONC), a leading clinical-stage company specializing in immunotherapy for oncology, summarized its biomarker and translational data for pelareorep, the Company's systemically delivered oncolytic virus. The data support pelareorep's mechanism of action and further strengthen the unique biological rationale and therapeutic potential for pelareorep as a platform immunotherapeutic. These include its ability to replicate in cancer cells, activate immune pathways, and drive T cell expansion and tumor infiltration in immunotherapy-resistant cancers. The translational research included the analysis of blood and tumor samples from patients in the GOBLET (pancreatic ductal adenocarcinoma (PDAC) and other gastrointestinal cancers) and AWARE-1 (breast cancer) studies. Analyses revealed consistent immune activation signatures, including: Upregulation of interferons, CXCL9/10/11, and PD-L1 Conversion of immunologically 'cold' tumors into 'hot' phenotypes Expansion and mobilization of tumor-infiltrating lymphocyte (TIL) clones in the blood, which correlates with a reduction in tumor size Modulation of the tumor microenvironment (TME) to enhance responsiveness to immune therapies "This robust data set, amassed from several studies in cancers that have historically resisted immunotherapeutic approaches, provides definitive validation of pelareorep's immune-mediated mechanism of action," said Dr. Thomas Heineman, Chief Medical Officer of Oncolytics. "We observed tumor biopsy-confirmed virus replication, immune cell activation, and the recruitment of cytotoxic T cells into the TME – all consistent with the durable responses observed in patients with metastatic PDAC and HR+/HER2- breast cancer who were treated with pelareorep." "The collection of data here show that pelareorep works how a cancer immunotherapy should work," said Jared Kelly, Chief Executive Officer of Oncolytics. "Pelareorep is a versatile product candidate with strong platform potential to enhance immunological responses in multiple indications, including hard-to-treat cancers. Such compelling findings should be exciting to strategic partners focused on finding a platform immunotherapy in large indications with high unmet medical needs." The GOBLET study continues to enroll PDAC and anal carcinoma patients, and additional translational data readouts are expected next year. The Company expects these and its other clinical data to support its focused and aggressive regulatory path and serve as the biological foundation for registration-enabled studies in immunotherapy-resistant solid tumors. As regulatory conversations progress throughout the summer, the Company expects to provide an updated clinical timeline before the end of the third quarter. About Oncolytics Biotech Inc. Oncolytics is a clinical-stage biotechnology company developing pelareorep, an intravenously delivered immunotherapeutic agent. Pelareorep has demonstrated promising results in two randomized Phase 2 studies in metastatic breast cancer and Phase 1 and 2 studies in pancreatic cancer. It acts by inducing anti-cancer immune responses and promotes an inflamed tumor phenotype – turning "cold" tumors "hot" – through innate and adaptive immune responses to treat a variety of cancers. Pelareorep has demonstrated synergies with multiple approved oncology treatments. Oncolytics is currently conducting and planning combination clinical trials with pelareorep in solid malignancies as it advances towards registrational studies in metastatic breast cancer and pancreatic cancer, both of which have received Fast Track designation from the FDA. For more about Oncolytics, please visit: or follow the company on social media on LinkedIn and on X @ oncolytics. This press release contains forward-looking statements, within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended and forward-looking information under applicable Canadian securities laws (such forward-looking statements and forward-looking information are collectively referred to herein as "forward-looking statements"). Forward-looking statements contained in this press release include statements regarding Oncolytics' belief as to the potential, mechanism of action and benefits of pelareorep as a cancer therapeutic; our plans, objectives and strategies; our expectation that our data supports our focused and aggressive regulatory path and serves as the biological foundation for registration-enabled studies in immunotherapy-resistant solid tumors; our plans to advance pelareorep into registration enabling studies in metastatic breast cancer and pancreatic cancer; and other statements related to anticipated developments in Oncolytics' business and technologies. In any forward-looking statement in which Oncolytics expresses an expectation or belief as to future results, such expectations or beliefs are expressed in good faith and are believed to have a reasonable basis, but there can be no assurance that the statement or expectation or belief will be achieved. Such forward-looking statements involve known and unknown risks and uncertainties, which could cause Oncolytics' actual results to differ materially from those in the forward-looking statements. Such risks and uncertainties include, among others, the availability of funds and resources to pursue research and development projects, the efficacy of pelareorep as a cancer treatment, the success and timely completion of clinical studies and trials, Oncolytics' ability to successfully commercialize pelareorep, uncertainties related to the research and development of pharmaceuticals, uncertainties related to the regulatory process and general changes to the economic environment. We may incur expenses or delays relating to events outside of our control, which could have a material adverse impact on our business, operating results and financial condition. Investors should consult Oncolytics' quarterly and annual filings with the Canadian and U.S. securities commissions for additional information on risks and uncertainties relating to the forward-looking statements. Investors are cautioned against placing undue reliance on forward-looking statements. The Company does not undertake any obligation to update these forward-looking statements, except as required by applicable laws. Company Contact Jon Patton Director of IR & Communication [email protected] Investor Relations for Oncolytics Mike Moyer LifeSci Advisors +1-617-308-4306 [email protected]
Cision Canada
2 hours ago
- Cision Canada
Greenlane Renewables Extends Credit Facility for $20 Million
VANCOUVER, BC, July 16, 2025 /CNW/ - Greenlane Renewables Inc. (" Greenlane" or the " Company") (TSX: GRN) (FSE: 52G) today announced that the Company has extended its standby letter of credit facility (the " Facility") to August 31, 2026 for a total of $20 million. The Facility is secured by a guarantee from Export Development Canada. "The extension of our credit facility reflects continued confidence in our business and financial strength while enhancing our ability to execute on growth initiatives, manage working capital," said Stephanie Mason, CFO of Greenlane. The Facility supports the Company's pursuit and fulfillment of larger projects and larger portfolios of projects in the global RNG market. About Greenlane Renewables Greenlane is driving change: accelerating the energy transition. We are cleaning up two of the largest and most difficult to decarbonize sectors of the global energy system: the natural gas grid and commercial transportation. As a pioneer and leading specialist in biogas desulfurization and upgrading, we have been actively contributing to the decarbonization of our planet for over 35 years with more than 355 systems supplied into 28 countries. We transform biogas generated from organic waste into high-value grid-ready renewable natural gas ("RNG") from a wide range of sources such as landfills, sugar mills, dairy farms, wastewater, and food waste. Greenlane is transforming energy production and creating new, sustainable revenue streams for its customers - all while dramatically reducing carbon emissions. Partner with us, let's accelerate the energy transition together. For further information, please visit FORWARD LOOKING INFORMATION – This news release contains "forward-looking information" within the meaning of applicable securities laws. All statements contained herein that are not historical in nature contain forward-looking information. Forward-looking information can be identified by words or phrases such as "may", "is expected", "likely", "should", "would", "plan", "anticipate", "intend", "potential", "proposed", "estimate", "believe" or the negative of these terms, or other similar words, expressions and grammatical variations thereof, or statements that certain events or conditions "can", "may" or "will" happen. In particular, this news release contains forward looking information regarding the Company's expectations that the extension of the credit facility reflects continued confidence in its business and financial strength, enhances its ability to execute on growth initiatives and manage working capital, and supports the pursuit and fulfillment of larger projects and portfolios in the global RNG market. The forward-looking information contained herein is made as of the date of this press release and is based on assumptions management believed to be reasonable at the time such statements were made, including management's perceptions of future growth and expected future developments, as well as other considerations that are believed to be appropriate in the circumstances. While management considers these assumptions to be reasonable based on information currently available to management, there is no assurance that such expectations will prove to be correct. By their nature, forward-looking information is subject to inherent risks and uncertainties that may be general or specific and which give rise to the possibility that expectations, forecasts, predictions, projections or conclusions will not prove to be accurate, that assumptions may not be correct and that objectives, strategic goals and priorities will not be achieved. A variety of factors, including known and unknown risks, many of which are beyond the Company's control, could cause actual results to differ materially from the forward-looking information in this press release. Additional risk factors can also be found in the Company's Management Discussion and Analysis, its Annual Information Form and in its base shelf prospectus dated January 4, 2024, all of which have been filed under the Company's SEDAR+ profile at Readers are cautioned not to put undue reliance on forward-looking information. The Company undertakes no obligation to update or revise any forward-looking information, whether as a result of new information, future events or otherwise, except as required by applicable law. Forward-looking statements contained in this news release are expressly qualified by this cautionary statement. SOURCE Greenlane Renewables Inc.
